Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

In addition, each group was further subdivided into a metabolic health group and a metabolic syndrome group according to ...

Korea University Guro Hospital has opened the Alzheimer's Prevention Center (Center Director Kang Sung-hoon).The Alzheimer's ...

Some researchers seek to establish a single abnormal result on a set of biomarker-based tests as sufficient to diagnose the ...

Leqembi’s sales continue to be underwhelming, according to analysts, who contend the companies’ Alzheimer’s disease therapy ...

Every anti-amyloid antibody is different, hence the donanemab AUR address two unique aspects of this drug: in its Phase 3 trial, scientists used baseline tau PET scans to determine eligibility, and ...

Q3 2024 Earnings Call Transcript November 6, 2024 Lantheus Holdings, Inc. beats earnings expectations. Reported EPS is $1.79, ...

King Faisal Specialist Hospital & Research Centre (KFSHRC) and Eli Lilly Saudi Arabia Limited (Lilly) have signed a ...

Diagnosis of Alzheimer's disease (AD) is currently largely based on the presence of biomarkers. This may lead to a ...